title: Postoperative progression of pulmonary metastasis in osteosarcoma.
abstract: Early relapse with distant metastasis often is observed in patients with cancer after resection of the primary tumor. It is considered that resection of the primary tumor induces activation of systemic angiogenesis and enhances progression of remote metastasis. The authors show that resection of the primary osteosarcoma tumor enhances progression of pulmonary metastasis in animal osteosarcoma models. Matrigel plug neovascularization assay revealed that systemic angiogenic activity was elevated after primary tumor removal (tumor intact group, 1.61 +/- 0.21 g/dL; tumor removed group, 4.92 +/- 0.35 g/dL). In addition, serum concentration of the angiogenesis inhibitor, endostatin, decreased significantly after primary tumor removal. Treatment with the antiangiogenic reagent TNP-470 suppressed postoperative progression of pulmonary metastasis. These results indicate the possibility that activation of angiogenic activity after resection of osteosarcoma tumors enhances progression of pulmonary metastasis. The current data also suggest that administration of antiangiogenic reagents can prevent progression of pulmonary metastasis in osteosarcoma postoperatively.
authors.affiliation: Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Japan.
authors.forename: Takeo
authors.initials: T
authors.lastname: Tsunemi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nagoya
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Kaya
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kawaguchi
authors.forename: Takuro
authors.initials: T
authors.lastname: Wada
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Yamashita
authors.forename: Seiichi
authors.initials: S
authors.lastname: Ishii
mesh_terms: D020533:Angiogenesis Inhibitors / Q000097:blood / Q000627:therapeutic use*; D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology* / Q000517:prevention & control / Q000601:surgery*; D003094:Collagen / Q000097:blood; D003510:Cyclohexanes; D004195:Disease Models, Animal; D043169:Endostatins; D016228:Endothelial Growth Factors / Q000097:blood; D005260:Female; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood / Q000517:prevention & control* / Q000556:secondary*; D008222:Lymphokines / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012516:Osteosarcoma / Q000517:prevention & control / Q000556:secondary* / Q000601:surgery*; D010446:Peptide Fragments / Q000097:blood; D011183:Postoperative Complications; D012717:Sesquiterpenes / Q000097:blood / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D043169:Endostatins; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D010446:Peptide Fragments; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D003094:Collagen; D000077609:O-(Chloroacetylcarbamoyl)fumagillol